354 related articles for article (PubMed ID: 28834809)
1. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
2. Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors.
Momeni Boroujeni A; Kertowidjojo E; Wu X; Soslow RA; Chiang S; Da Silva EM; Weigelt B; Chui MH
Mod Pathol; 2022 Nov; 35(11):1684-1694. PubMed ID: 36138078
[TBL] [Abstract][Full Text] [Related]
3. Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.
Lee JC; Lu TP; Changou CA; Liang CW; Huang HN; Lauria A; Huang HY; Lin CY; Chiang YC; Davidson B; Lin MC; Kuo KT
Mod Pathol; 2016 Sep; 29(9):1070-82. PubMed ID: 27255164
[TBL] [Abstract][Full Text] [Related]
4. DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation.
Bean GR; Anderson J; Sangoi AR; Krings G; Garg K
Mod Pathol; 2019 Feb; 32(2):280-289. PubMed ID: 30266945
[TBL] [Abstract][Full Text] [Related]
5. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
[TBL] [Abstract][Full Text] [Related]
6. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
7. Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma.
Yoon JY; de Kock L; Stewart CJR; McCluggage WG; Foulkes WD; Clarke BA; Rouzbahman M
Cancer Treat Res Commun; 2021; 27():100363. PubMed ID: 33838572
[TBL] [Abstract][Full Text] [Related]
8. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
9. Cluster of uterine mullerian adenosarcoma in the Washington, DC metropolitan area with high incidence of sarcomatous overgrowth.
Seidman JD; Wasserman CS; Aye LM; MacKoul PJ; O'Leary TJ
Am J Surg Pathol; 1999 Jul; 23(7):809-14. PubMed ID: 10403304
[TBL] [Abstract][Full Text] [Related]
10. [Prognosis-related clinicopathologic characteristics of FIGO stage Ⅰ Müllerian adenosarcoma of uterus].
Wang Y; Liu AJ; Chen X; Song X
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):334-338. PubMed ID: 29783798
[No Abstract] [Full Text] [Related]
11. Management of uterine adenosarcomas with and without sarcomatous overgrowth.
Tanner EJ; Toussaint T; Leitao MM; Hensley ML; Soslow RA; Gardner GJ; Jewell EL
Gynecol Oncol; 2013 Apr; 129(1):140-4. PubMed ID: 23283300
[TBL] [Abstract][Full Text] [Related]
12. Uterine Adenosarcoma.
Ulrich UA; Denschlag D
Oncol Res Treat; 2018; 41(11):693-696. PubMed ID: 30326467
[TBL] [Abstract][Full Text] [Related]
13. The Impact on Survival of an Extensive Sex Cord-like Component in Mullerian Adenosarcomas: A Study Comprising 6 Cases.
Stolnicu S; Molnar C; Barsan I; Boros M; Nogales FF; Soslow RA
Int J Gynecol Pathol; 2016 Mar; 35(2):147-52. PubMed ID: 26535983
[TBL] [Abstract][Full Text] [Related]
14. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
15. Uterine adenosarcomas are mesenchymal neoplasms.
Piscuoglio S; Burke KA; Ng CK; Papanastasiou AD; Geyer FC; Macedo GS; Martelotto LG; de Bruijn I; De Filippo MR; Schultheis AM; Ioris RA; Levine DA; Soslow RA; Rubin BP; Reis-Filho JS; Weigelt B
J Pathol; 2016 Feb; 238(3):381-8. PubMed ID: 26592504
[TBL] [Abstract][Full Text] [Related]
16. Uterine Adenosarcoma.
Pinto A; Howitt B
Arch Pathol Lab Med; 2016 Mar; 140(3):286-90. PubMed ID: 26927725
[TBL] [Abstract][Full Text] [Related]
17. Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma.
de Kock L; Yoon JY; Apellaniz-Ruiz M; Pelletier D; McCluggage WG; Stewart CJR; Dickson BC; Rouzbahman M; Clarke BA; Foulkes WD
Mod Pathol; 2020 Jun; 33(6):1207-1219. PubMed ID: 31900434
[TBL] [Abstract][Full Text] [Related]
18. Targeted genomic analysis of Müllerian adenosarcoma.
Howitt BE; Sholl LM; Dal Cin P; Jia Y; Yuan L; MacConaill L; Lindeman N; Kuo F; Garcia E; Nucci MR; Quade BJ
J Pathol; 2015 Jan; 235(1):37-49. PubMed ID: 25231023
[TBL] [Abstract][Full Text] [Related]
19. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S78-82. PubMed ID: 25341585
[TBL] [Abstract][Full Text] [Related]
20. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]